Is the new bivalent COVID-19 vaccine the booster we’ve been waiting for?

Kyver­na Ther­a­peu­tics, one of the clin­i­cal-stage biotechs at the fore­front of CAR-T cell ther­a­py’s ex­pan­sion in­to au­toim­mune dis­eases, is con­sid­er­ing an IPO as ear­ly as

Ei­sai has slashed Leqem­bi’s sales fore­cast by 25% this year, low­er­ing the ceil­ing for one of the in­dus­try’s most close­ly-watched drugs. The com­pa­ny now ex­pects